The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Challenges and Countermeasures of Pharmaceutical Enterprises under the Background of Centralized Purchasing of Drugs "4+7"
Author(s): 
Pages: 13-15,19
Year: Issue:  8
Journal: Health Economics Research

Keyword:  药品采购带量集中采购以价换量医药企业;
Abstract: 为降低虚高药价、避免过度医疗、斩断医药行业的腐败链条,我国自2018年开始试行药品“4+7”带量采购政策.这一政策的出台引发行业巨震:中标药品价格大幅下降,药品市场重新洗牌,中小型药企举步维艰,大规模创新型药企释放政策红利.对此,提出新政背景下医药企业转型发展的应对建议.
Related Articles
No related articles found